Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis

The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS

(2012) David V Ford et al.   BMC Medical Informatics and Decision Making

Using Health State Utility Values in Models Exploring the Cost-Effectiveness of Health Technologies

(2012) Roberta Ara et al.   VALUE IN HEALTH

Deriving Input Parameters for Cost-Effectiveness Modeling: Taxonomy of Data Types and Approaches to Their Statistical Synthesis

(2012) Pedro Saramago et al.   VALUE IN HEALTH

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

(2012) Stephanie R. Earnshaw et al.   Applied Health Economics and Health Policy

Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying Therapy

(2011) Suellen M. Curkendall et al.   CLINICAL THERAPEUTICS

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study

(2011) K. Noyes et al.   NEUROLOGY

Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis

(2011) Ken O’Day et al.   JOURNAL OF MEDICAL ECONOMICS

Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis

(2010) Howard L. Zwibel   ADVANCES IN THERAPY

Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort

(2010) John P Zajicek et al.   BMC Neurology

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective

(2010) Mark Nuijten et al.   CLINICAL THERAPEUTICS

Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation

(2010) Krithika Rajagopalan et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis

(2010) Jessica Sharac et al.   DRUGS

Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study

(2010) H. Tan et al.   Multiple Sclerosis Journal

The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature

(2010) Huseyin Naci et al.   JOURNAL OF MEDICAL ECONOMICS

Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis

(2009) P Tappenden et al.   BONE MARROW TRANSPLANTATION

Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis

(2009) Evelyn Chiao et al.   CURRENT MEDICAL RESEARCH AND OPINION

Systematic reviews of economic evaluations: utility or futility?

(2009) Rob Anderson   HEALTH ECONOMICS

Is Short-Term Palliative Care Cost-Effective in Multiple Sclerosis? A Randomized Phase II Trial

(2009) Irene J. Higginson et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions

(2009) G Kobelt et al.   Multiple Sclerosis Journal

Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b

(2009) Carlo Lazzaro et al.   NEUROLOGICAL SCIENCES

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

(2009) Ray Gani et al.   PHARMACOECONOMICS

Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a

(2009) Shien Guo et al.   PHARMACOECONOMICS

Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population

(2009) Paul Tappenden et al.   VALUE IN HEALTH

The cost effectiveness and budget impact of natalizumab for formulary inclusion

(2009) Justin Bakhshai et al.   JOURNAL OF MEDICAL ECONOMICS

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

(2008) Jane Castelli-Haley et al.   ADVANCES IN THERAPY

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden

(2008) G Kobelt et al.   Multiple Sclerosis Journal

Disability as an outcome in MS clinical trials

(2008) G. C. Ebers et al.   NEUROLOGY

Multiple Sclerosis in the UK

(2008) Paul McCrone et al.   PHARMACOECONOMICS

Cost–effectiveness of natalizumab in multiple sclerosis

(2008) Trygve Holmoy et al.   Expert Review of Pharmacoeconomics & Outcomes Research